Lead Product(s): Ligelizumab
Therapeutic Area: Immunology Product Name: QGE031
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2021
Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines.
Lead Product(s): Tislelizumab
Therapeutic Area: Oncology Product Name: BGB-A317
Highest Development Status: Undisclosed Product Type: Large molecule
Deal Size: $2,200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
Novartis Pharma will develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union, United Kingdom, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan.